Daclizumab to Treat Chronic Immune Thrombocytopenia

NCT00049725 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

NIH

Sponsor class

Conditions

Thrombocytopenia

Interventions

DRUG: Daclizumab

Sponsor

National Institutes of Health Clinical Center (CC)